The efficacy of tumor eradication in mice by VEGFR2-targeting CAR T cells could be improved by co-expression of secreted IL-12 [60] or IL-15 in CAR T cells [61], while no overt toxicities against normal tissues were reported that would generally preclude the use of VEGFR2 as a target for CAR T cells. The gene discussed is KDR; the disease is neoplasm.